According to filings with the U.S. Securities and Exchange Commission, Lento Bio is raising $5,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Kris Barnes played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Lento Bio
Lento Bio was formed in 2022 in collaboration with Ichor Life Sciences and Clarkson University’s Shipley Center for Innovation, with the goal to develop effective, safe, and durable treatments for chronic age-related disease by using small molecules to directly target molecular damage. Our primary focus is the removal of Advanced Glycation End Products (AGEs), initially focusing on damage to the lens in presbyopia while also exploring further opportunities in systemic disease.

To learn more about Lento Bio, visit http://lentobio.com/

Contact:
Kris Barnes, Chief Executive Officer
646-676-0476
https://www.linkedin.com/in/kris-barnes-phd-7912a734

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.